Johnson & Johnson Expands Neuropsychiatry Portfolio with New Data on Bipolar Mania, Depression, and Schizophrenia — Johnson & Johnson

Event summary

Johnson & Johnson will present 24 abstracts featuring clinical data and real-world evidence across its neuropsychiatry portfolio at the 2026 Psych Congress Annual Meeting (September 15-19, New Orleans, LA).
New pivotal Phase 3 data evaluating the efficacy and safety of CAPLYTA® (lumateperone) in bipolar mania will be presented, reinforcing its potential across mood disorders.
Additional data on SPRAVATO® (esketamine) nasal spray and Phase 3 clinical trial data for seltorexant in major depressive disorder (MDD) with insomnia symptoms will also be presented.
The presentations reflect Johnson & Johnson's commitment to advancing research across mood disorders, focusing on areas with significant treatment challenges.

The big picture

Johnson & Johnson's presentation of new neuropsychiatry data at Psych Congress 2026 underscores its strategic focus on expanding its portfolio in mood disorders. The company is positioning itself to address significant treatment challenges in bipolar mania, depression, and schizophrenia, leveraging both clinical trials and real-world evidence. This move aligns with broader industry trends toward personalized and targeted therapies in mental health, where the need for effective treatments remains high. The scale of Johnson & Johnson's neuropsychiatry portfolio and its commitment to advancing research could potentially reshape the landscape for patients and clinicians alike.

What we're watching

Clinical Validation: How the new data on CAPLYTA® in bipolar mania will impact its market position and adoption rates among clinicians.
Treatment Innovation: Whether the focus on complex, high-burden neuropsychiatric conditions will drive differentiation in a competitive market.
Regulatory Landscape: The pace at which regulatory approvals for seltorexant and other investigational therapies will progress, given the emphasis on addressing unmet needs in mood disorders.